Drug and Alcohol Rehabilitation: Induced Pluripotent Stem Cells Used to Reveal Drug Actions in a Long QT Syndrome Family With Complex Genetics.

Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.

Filed under: Drug and Alcohol Rehabilitation

J Gen Physiol. 2013 Jan; 141(1): 61-72
Terrenoire C, Wang K, Chan Tung KW, Chung WK, Pass RH, Lu JT, Jean JC, Omari A, Sampson KJ, Kotton DN, Keller G, Kass RS

Understanding the basis for differential responses to drug therapies remains a challenge despite advances in genetics and genomics. Induced pluripotent stem cells (iPSCs) offer an unprecedented opportunity to investigate the pharmacology of disease processes in therapeutically and genetically relevant primary cell types in vitro and to interweave clinical and basic molecular data. We report here the derivation of iPSCs from a long QT syndrome patient with complex genetics. The proband was found to have a de novo SCN5A LQT-3 mutation (F1473C) and a polymorphism (K897T) in KCNH2, the gene for LQT-2. Analysis of the biophysics and molecular pharmacology of ion channels expressed in cardiomyocytes (CMs) differentiated from these iPSCs (iPSC-CMs) demonstrates a primary LQT-3 (Na(+) channel) defect responsible for the arrhythmias not influenced by the KCNH2 polymorphism. The F1473C mutation occurs in the channel inactivation gate and enhances late Na(+) channel current (I(NaL)) that is carried by channels that fail to inactivate completely and conduct increased inward current during prolonged depolarization, resulting in delayed repolarization, a prolonged QT interval, and increased risk of fatal arrhythmia. We find a very pronounced rate dependence of I(NaL) such that increasing the pacing rate markedly reduces I(NaL) and, in addition, increases its inhibition by the Na(+) channel blocker mexiletine. These rate-dependent properties and drug interactions, unique to the proband’s iPSC-CMs, correlate with improved management of arrhythmias in the patient and provide support for this approach in developing patient-specific clinical regimens.
HubMed – drug

 

Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis.

Filed under: Drug and Alcohol Rehabilitation

Mol Biol Rep. 2013 Jan 1;
Du H, Chen X, Fang Y, Yan O, Xu H, Li L, Li W, Huang W

Pathogenesis and genetic factors influencing predisposition to antituberculosis drug-induced hepatotoxicity (ATDH) are not clear. Polymorphism at the genetic locus of a drug and xenobiotic compound metabolizing enzyme, N-acetyltransferase type 2 (NAT2), is reported to be associated with the excess generation of toxic reactive metabolites. To date, many case-control studies have been carried out to investigate the relationship between the NAT2 polymorphisms and ATDH, but the results have been inconsistent. To investigate this inconsistency, a meta-analysis was performed. Databases including PubMed, Web of Science, EMBASE and CNKI were searched to find relevant studies. A total of 26 case-control studies, involving 1,198 cases and 2,921 controls were included. Overall, we found significant association between slow acetylator genotype of NAT2 and ATDH (OR = 3.10, 95 % CI: 2.47-3.88, P < 10(-5)). Significant results were also found in East Asians, South Asians, Brazilians and Middle Eastern when stratified by ethnicity. However, no significant associations were found for Caucasians. This meta-analysis demonstrated that the slow acetylator genotype of NAT2 is a risk factor associated with increased ATDH susceptibility, but these associations vary in different ethnic populations. HubMed – drug

 

Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations.

Filed under: Drug and Alcohol Rehabilitation

Mol Biol Rep. 2013 Jan 1;
López M, Dorado P, Ortega A, Peñas-Lledó E, Monroy N, Silva-Zolezzi I, Cobaleda J, Gallego-Aguilera A, Alonso ME, Llerena A

UDP-glucuronosyltransferase 1A4 (UGT1A4) is a phase II drug-metabolizing enzyme that catalyzes the glucuronidation of many clinically-important drugs. Interethnic differences in the genetic polymorphism of UGT1A4 have been reported; however, there is no information in Mexican Mestizos (MMs) and Spaniards (SPs). Furthermore, MM is an admixed population with 26 % of Caucasian genes mainly from Spain. Therefore, this study aimed to investigate the potential differences between 318 SPs and 248 MMs healthy individuals regarding UGT1A4*1b, UGT1A4*2 and UGT1A4*3 alleles and to compare the observed frequencies with those previously reported in different populations. The allelic frequencies of the three UGT1A4 polymorphisms showed interethnic differences between MMs and SPs (p < 0.05). The analyzed SNPs variants in this genetic region were not in linkage disequilibrium (LD) for the MM population, suggesting that these mutations have arisen independently in the same genetic background. In contrast, UGT1A4*2 and UGT1A4*3 were in LD in the SP population. Comparison of present data with other in different ethnic groups revealed that the frequencies of UGT1A4*2 and UGT1A4*3 in SP were similar to other Caucasians and higher than in Asians, whereas in MMs were lower than in Caucasians and higher than in Asians only for UGT1A4*2. Present results could be helpful to improve the use of UGT1A4 drug substrates in order to adjust them to the ethnic background of a given population, specifically for Hispanics. HubMed – drug

 


 

Dr. Montes: Neurobiology of Addiction Part 4 – Dr. Montes shares his insight on the neurobiology of addiction. Call (877) 446-1342 for a confidential consultation. We are a nationally recognized drug and alcohol treatment center committed to providing compassionate care to each of our patients. The Joint Commissions on Accreditations of Health Care Organizations has awarded The Treatment Center Gold Seal Accreditation for our superior quality of care in the substance abuse treatment centers field. Our staff is a team of highly trained, highly skilled addiction professionals who understand the complexities of addiction and treat the disease through contemporary methods. We offer the following services: • In-patient Drug and Alcohol Rehabilitation • Full Medical Drug and Alcohol Detox by Board Certified Physicians • Dual Diagnosis Substance Abuse Treatment • Individual and Group Therapy • Holistic Pain Treatment (following pain pill detox) • Acupuncture • Massage Therapy • Cognitive Behavior Therapy • EMDR Therapy In addition to our traditional residential treatment program, we offer a Christian substance abuse treatment center, Road Less Traveled. We also offer our GO program, designed to assist our patients transition from in-patient treatment to sober living.

 

Find More Drug And Alcohol Rehabilitation Information…